NCT05470725View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Hypertension
Interventions
DRUG

CIN-107

A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33603

Genesis Clinical Trials, Tampa

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY